
Annual report 2022
added 08-16-2022
Happiness Biotech Group Limited Net Income 2011-2026 | HAPP
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Happiness Biotech Group Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -49.2 M | 786 K | 12.7 M | 18.7 M | 17.5 M | 14.5 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.7 M | -49.2 M | 2.5 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
Ultragenyx Pharmaceutical
RARE
|
-575 M | $ 19.23 | -3.85 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | ||
|
RedHill Biopharma Ltd.
RDHL
|
-97.7 M | $ 0.8 | 0.89 % | $ 428 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
17.2 B | $ 13.56 | -1.56 % | $ 2.25 B | ||
|
Regeneron Pharmaceuticals
REGN
|
4.5 B | $ 742.02 | -1.94 % | $ 77.6 B | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | ||
|
Replimune Group
REPL
|
-247 M | $ 7.22 | -4.24 % | $ 582 M | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
REGENXBIO
RGNX
|
-194 M | $ 7.88 | -4.6 % | $ 406 M | ||
|
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | ||
|
Rigel Pharmaceuticals
RIGL
|
367 M | $ 26.2 | -0.64 % | $ 471 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | ||
|
Avidity Biosciences
RNA
|
-685 M | $ 13.09 | -0.08 % | $ 1.8 B | ||
|
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
-197 M | $ 78.52 | -4.13 % | $ 5.1 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 12.57 | -9.96 % | $ 1.91 B | ||
|
Sana Biotechnology
SANA
|
-244 M | $ 2.78 | -8.42 % | $ 704 M | ||
|
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B | ||
|
SIGA Technologies
SIGA
|
23.3 M | $ 5.35 | 7.76 % | $ 383 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 321.71 | -1.96 % | $ 42.1 B | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | ||
|
Silence Therapeutics plc
SLN
|
-39.4 M | $ 4.8 | -9.6 % | $ 622 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
-15 M | $ 1.08 | -0.92 % | $ 22.2 M | ||
|
Enochian Biosciences
ENOB
|
-178 M | - | - | $ 40.5 M |